Characterization of doravirine-selected resistance patterns from participants in treatment-naive Phase 3 clinical trials

被引：0
|
作者：
Lai, M. -T. [1 ]
Xu, M. [2 ]
Ngo, W. [3 ]
Feng, M. [3 ]
Hazuda, D. [3 ]
Hanna, G. [4 ]
Kumar, S. [5 ]
Xu, X. [6 ]
Martin, E. [4 ]
Hwang, C. [4 ]
机构：
[1] Merck & Co Inc, Kenilworth, NJ USA
[2] Merck & Co Inc, Dept Pharmacol, West Point, PA USA
[3] Merck & Co Inc, Dept Antiviral Res, West Point, PA USA
[4] Merck & Co Inc, Dept Clin Res, West Point, PA USA
[5] Merck & Co Inc, Dept Clin Sci & Study Management, West Point, PA USA
[6] Merck & Co Inc, Dept Biostat, West Point, PA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2018年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
THPDB0101
引用
收藏
页码：137 / 138
页数：2
相关论文
共 50 条
  • [31] Analysis of pooled data from clinical trials in treatment-naive patients with late-onset Pompe disease (LOPD) to inform on the efficacy of avalglucosidase alfa
    Mozaffar, Tahseen
    Franca, Lionel Riou
    Msihid, Jerome
    Shukla, Pragya
    Proskorovsky, Irina
    Zhou, Tianyue
    Fournier, Marie
    Periquet, Magali
    Haack, Kristina An
    Pollissard, Laurence
    Straub, Volker
    MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S86 - S86
  • [32] National and Regional US Antibiotic Resistance to Helicobacter pylori Identified From a Phase 3 Clinical Trial of Treatment Naive Patients in the United States
    Hulten, Kristina G.
    Graham, David Y.
    Bibliowicz, Aida
    Kalfus, Ira N.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S695 - S695
  • [33] Response to Letter to the Editor From Malozowski: "Weekly Lonapegsomatropin in Treatment-Naive Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"
    Thornton, Paul S.
    Maniatis, Aristides K.
    Aghajanova, Elena
    Chertok, Elena
    Lin, Zhengning
    Song, Wenjie
    Christoffersen, Eva Dam
    Breinholt, Vibeke Miller
    Giorgadze, Elene
    Korpal-Szczyrska, Maria
    Hofman, Paul L.
    Karpf, David B.
    Shu, Aimee D.
    Beckert, Michael
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (05): : E2215 - E2216
  • [34] Safety and efficacy of long-term velaglucerase alfa therapy in treatment-naive adults with type 1 Gaucher disease: results from Phase III trials
    Giraldo, Pilar
    Zimran, Ari
    Mehta, Atul
    Hughes, Derralynn
    Hangartner, Thomas N.
    Wang, Nan
    Cohn, Gabriel M.
    Crombez, Eric
    Elstein, Deborah
    MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S47 - S47
  • [35] NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS
    Zeuzem, S.
    Jensen, D. M.
    Carvalho, A.
    Diago, M.
    Feinman, S. V.
    Kowdley, K. V.
    Kao, J. -H.
    Maevskaya, M.
    Negro, F.
    Mantry, P.
    Tanaka, Y.
    Forton, D.
    Genne, D.
    Paik, S. W.
    Zehnter, E.
    Kuboki, M.
    Lee, W. M.
    Peng, C. -Y.
    Yatsuhashi, H.
    Stern, J. O.
    Datsenko, Y.
    Drulak, M.
    Voss, F.
    Boecher, W.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S451 - S451
  • [36] Transmitted NNRTI resistance does not impact the efficacy of EVG/c/FTC/TAF (or TDF) in two randomised clinical trials in treatment-naive patients living with HIV-1
    Mackie, N.
    Antonucci, S.
    Rogatto, F.
    Callebaut, C.
    Margot, N.
    HIV MEDICINE, 2019, 20 : 23 - 24
  • [37] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
    Jensen, Christopher M.
    Lipton, Richard B.
    Blumenfeld, Andrew
    Croop, Robert
    Thiry, Alexandra
    L'Italien, Gilbert
    Morris, Beth A.
    Coric, Vladimir
    Goadsby, Peter J.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 116 - 117
  • [38] Rimegepant for the Acute Treatment of Migraine: Subgroup Analyses From 3 Phase 3 Clinical Trials by Triptan Treatment Experience
    Jensen, C. M.
    Lipton, R.
    Blumenfeld, A.
    Croop, R.
    Thiry, A. C.
    L'Italien, G.
    Morris, B.
    Coric, V.
    Goadsby, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [39] PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS
    Zeuzem, S.
    Demasi, R.
    Foster, G. R.
    Buti, M.
    Baldini, A.
    Luo, D.
    Witek, J.
    Rizzetto, M.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S452 - S452
  • [40] Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial
    Xu, Hua
    Yao, Xin
    He, Zhisong
    Luo, Hong
    Li, Guiling
    Guo, Jianming
    Diao, Lei
    Fan, Yu
    Li, Yuan
    Fan, Jiquan
    Hu, Xiaoyi
    Lu, Puhan
    Shi, Haiyan
    Chen, Keyan
    Tan, Panfeng
    Fan, Songhua
    Shi, Michael
    Su, Weiguo
    Ye, Dingwei
    TARGETED ONCOLOGY, 2025, 20 (01) : 113 - 125
12345